載入...
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
Interleukin-2 (IL-2) is an established therapeutic agent used for cancer immunotherapy. Since treatment efficacy is mediated by CD8(+) and NK cell activity at the tumour site, considerable efforts have focused on generating variants that expand these subsets systemically, as exemplified by IL-2/anti...
Na minha lista:
| 發表在: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5437307/ https://ncbi.nlm.nih.gov/pubmed/28497796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms15373 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|